Core Viewpoint - Furuya Medical Technology (01696) reported a revenue of $165 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 1.9% [1] - The company's net profit attributable to shareholders was $6.426 million, down 41.3% year-on-year, with basic earnings per share at 1.37 cents [1] Group 1: Revenue and Market Conditions - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending [1] - Transportation delays in June due to regional tensions also contributed to a slight delay in revenue recognition [1] - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] Group 2: Profitability and Cost Structure - The gross profit margin decreased from 62.4% in 2024 to 60.0% in the reporting period [1] - The reduction in gross margin is mainly due to a strategic shift in the product mix towards core professional-grade and precision high-end products, which have higher material costs due to the use of top-tier technology specifications [1] - The decline in revenue contribution from North America also impacted the overall profitability [1] Group 3: Order Backlog - As of June 30, 2025, the order backlog remains robust, increasing by several million dollars compared to the same period in 2024 [1]
复锐医疗科技发布中期业绩，股东应占溢利642.6万美元，同比下降41.3%